NR3C2 and chronic kidney disease: A post-hoc analysis of the DAPA-CKD trial investigated the influence of baseline MR antagonists on the primary outcomes of dapagliflozin administration in patients with CKD, revealing that the efficacy of SGLT2 inhibitors remained unaffected by the presence of MR antagonists [55].